The presence of a TET2 mutation, similar to the presence of an IDH mutation, drastically increased sensitivity to venetoclax-based therapies in newly diagnosed, relapsed and refractory AML patients, with CR/CRi rates up to 86% compared to 39% in patients with wild-type TET2 (Table 3) [37,48]. The gene discussed is TET2; the disease is acute myeloid leukemia.